PatientsVille.com LogoPatientsVille.com

Thyroid Disease | Local Triamcinolone Injection in Active Thyroid Orbitopathy

Thyroid Disease research study

What is the primary objective of this study?

Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.

Who is eligible to participate?

Inclusion Criteria: - Age>18 years. - Active thyroid orbitopathy according to clinical activity score>=3. Exclusion Criteria: - Intraorbital or active infections. - Tuberculosis. - Other orbital disease. - Pregnancy. - Compressive optic neuropathy. - Systemic steroid therapy within 6 months of study start.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Thyroid Disease

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:TriamcinoloneSubconjunctival and peribulbar, 40 mg/ml, 3 monthly injection

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Triamcinolone

Study Status

Unknown status

Start Date: February 2011

Completed Date: February 2013

Phase: N/A

Type: Interventional

Design:

Primary Outcome: Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy .

Secondary Outcome: To check if the level of TSH Receptor antibodies are affected by the local injection.

Study sponsors, principal investigator, and references

Principal Investigator: Daniel Briscoe, MD

Lead Sponsor: HaEmek Medical Center, Israel

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01280214

Discuss Aristospan